[{"id":"afc34dd5-440d-4768-b2d3-1f68bbdafbb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05470491","created_at":"2022-07-22T11:56:13.684Z","updated_at":"2025-02-25T13:54:33.177Z","phase":"Phase 1/2","brief_title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","source_id_and_acronym":"NCT05470491","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-20"},{"id":"37f445e0-3beb-40a4-8567-9de16b5cc533","acronym":"PICCASSO","url":"https://clinicaltrials.gov/study/NCT03274804","created_at":"2021-01-17T18:04:47.498Z","updated_at":"2024-07-02T16:36:09.249Z","phase":"Phase 1","brief_title":"Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC","source_id_and_acronym":"NCT03274804 - PICCASSO","lead_sponsor":"University Hospital Heidelberg","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Selzentry (maraviroc)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2022-06-07"},{"id":"5fad71d4-a395-4a9d-9bc6-39b3d673e45a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01276236","created_at":"2021-01-29T07:01:30.935Z","updated_at":"2024-07-02T16:36:33.752Z","phase":"Phase 2","brief_title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","source_id_and_acronym":"NCT01276236","lead_sponsor":"University of California, San Francisco","biomarkers":" CD8 • CD38 • CD4 • CD69","pipe":" | ","alterations":" CD38 positive • CD8 negative","tags":["CD8 • CD38 • CD4 • CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive • CD8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Selzentry (maraviroc)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 03/09/2011","start_date":" 03/09/2011","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 04/30/2015","study_completion_date":" 04/30/2015","last_update_posted":"2021-03-05"},{"id":"ffc131aa-8b13-4488-9640-fb3e7099359c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01785810","created_at":"2021-01-18T07:53:06.683Z","updated_at":"2024-07-02T16:36:36.243Z","phase":"Phase 2","brief_title":"Phase II Maraviroc for GVHD Prevention","source_id_and_acronym":"NCT01785810","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Selzentry (maraviroc)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 11/11/2016","primary_completion_date":" 11/11/2016","study_txt":" Completion: 07/12/2018","study_completion_date":" 07/12/2018","last_update_posted":"2021-01-11"},{"id":"7f7f457c-8537-4dab-a39c-3cd7146b8eeb","acronym":"BMT CTN 1203","url":"https://clinicaltrials.gov/study/NCT02208037","created_at":"2021-01-18T10:20:24.000Z","updated_at":"2024-07-02T16:37:03.564Z","phase":"Phase 2","brief_title":"Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)","source_id_and_acronym":"NCT02208037 - BMT CTN 1203","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Selzentry (maraviroc) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 279","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 10/01/2017","study_completion_date":" 10/01/2017","last_update_posted":"2019-01-23"}]